SAHPRA HIV treatment approval: Lenacapavir's impact on South Africa
Lenacapavir's recent approval by SAHPRA marks a significant advancement in HIV treatment options for South Africans, promising improved patient outcomes.
Quick Answer
Lenacapavir's recent approval by SAHPRA marks a significant advancement in HIV treatment options for South Africans, promising improved patient outcomes.
Key Questions
- What is lenacapavir and how does it work for HIV prevention?
- When did SAHPRA approve lenacapavir for HIV prevention?
- Who is eligible for lenacapavir PrEP in South Africa?
- What clinical evidence supports lenacapavir's efficacy for HIV PrEP?
- Why is South Africa's approval significant for HIV prevention in Africa?
The South African Health Products Regulatory Authority (SAHPRA) approved lenacapavir on October 27, 2025, making South Africa the first African nation to register this twice-yearly injectable HIV prevention therapy. The approval addresses critical adherence barriers in a country with the world's largest HIV burden.
Contents10 sections
Key Takeaways
- First in Africa: SAHPRA's October 27, 2025 approval makes South Africa the first African country to register lenacapavir for HIV-1 pre-exposure prophylaxis (PrEP), following FDA approval in June 2025.
- Expedited review: The seven-month regulatory timeline from Gilead's March 2025 submission was enabled through the EU-M4all procedure with the European Medicines Agency.
- Clinical efficacy: Phase 3 PURPOSE 1 trial (NCT04994509) demonstrated 100% efficacy with zero HIV infections in 5,268 participants receiving lenacapavir versus 16 infections in the oral PrEP comparator arm.
- Dosing advantage: Six-monthly subcutaneous injections eliminate daily pill burden, addressing adherence challenges that limit oral PrEP effectiveness in real-world settings.
- Public health impact: South Africa carries approximately 7.8 million people living with HIV—the highest national total globally—making this approval critical for epidemic control.
What Is Lenacapavir?
Lenacapavir is a first-in-class HIV-1 capsid inhibitor developed by Gilead Sciences. Unlike existing PrEP options that target reverse transcriptase or integrase enzymes, lenacapavir blocks viral replication by binding to the capsid protein that surrounds HIV's genetic material.
The drug is given as a subcutaneous injection every six months. Treatment starts with two 300 mg tablets on day 1, a 927 mg injection on day 1, and two more 300 mg tablets on day 2. The drug stays active for six months. Patients do not need daily pills.
What Clinical Evidence Supports SAHPRA's Approval?
SAHPRA based its approval on the Phase 3 PURPOSE program. The PURPOSE 1 trial (NCT04994509) enrolled 5,268 women and girls aged 16–25 across South Africa and Uganda.
Key efficacy findings from PURPOSE 1 include:
| Outcome | Lenacapavir Arm | Oral PrEP Comparator |
|---|---|---|
| HIV infections | 0 | 16 |
| Incidence rate | 0.00 per 100 person-years | 1.69 per 100 person-years |
| Efficacy | 100% (95% CI: not estimable) | Baseline comparator |
| Participants | 2,134 | 1,068 |
The FDA approved lenacapavir (branded as Yeztugo) for PrEP on June 18, 2025. The FDA label warns about drug resistance risk if lenacapavir starts in patients with undiagnosed HIV-1 infection.
How Did SAHPRA Complete Review in Seven Months?
Gilead submitted its marketing application to SAHPRA in March 2025. The review proceeded through the EU-Medicines for All (EU-M4all) procedure, a regulatory pathway enabling the European Medicines Agency to provide scientific opinions on high-priority medicines intended for markets outside the European Union.
This collaboration let SAHPRA use EMA expertise while keeping independent authority. SAHPRA CEO Dr. Boitumelo Semete-Makokotlela called the drug "the most effective HIV prevention measure thus far."
What Is South Africa's HIV Burden?
South Africa faces the world's highest HIV prevalence. According to UNAIDS, approximately 7.8 million people in the country are living with HIV—the largest national total globally. Sub-Saharan Africa as a region carries approximately two-thirds of all people living with HIV worldwide.
Prevention remains critical even as treatment access grows. Daily oral PrEP works in trials but faces adherence challenges in practice. A twice-yearly injection closes this gap.
Who Can Access Lenacapavir in South Africa?
SAHPRA approved lenacapavir for:
- Adults and adolescents weighing at least 35 kg
- Individuals at risk of HIV-1 acquisition
- Candidates must test HIV-negative before initiation and before each injection
Patients must combine lenacapavir with safer sex practices. Providers must verify negative HIV status before each injection using an FDA-cleared test.
What Are the Safety Considerations?
The FDA prescribing information includes a boxed warning about drug resistance risk. Individuals who initiate lenacapavir with undiagnosed HIV-1 infection may develop capsid inhibitor-resistant viral variants. This risk necessitates:
- HIV-1 screening before initiating therapy
- Testing before each subsequent injection
- Immediate transition to a complete HIV treatment regimen if infection occurs during PrEP
Common adverse reactions in clinical trials included injection site reactions, headache, and nausea. The safety profile supported approval for the indicated population.
How Will Lenacapavir Reach Patients?
Gilead has committed to rapid access in high-burden regions. In November 2025, the company announced delivery of first shipments to Eswatini and Zambia through partnerships with the Global Fund and PEPFAR. South Africa's approval positions it to receive supply through similar mechanisms.
Pricing and procurement details remain under negotiation. Generic versions will expand access after patent expiry. Gilead aims to enable sustainable availability in low-income countries.
Frequently Asked Questions
What is lenacapavir and how does it work for HIV prevention?
Lenacapavir is a first-in-class HIV-1 capsid inhibitor approved for pre-exposure prophylaxis (PrEP). It blocks HIV replication by targeting the viral capsid protein. Unlike daily oral PrEP options, lenacapavir is administered as a subcutaneous injection every six months after initial oral loading doses on days 1 and 2.
When did SAHPRA approve lenacapavir for HIV prevention?
SAHPRA approved lenacapavir on October 27, 2025. The regulatory review took approximately seven months from Gilead's submission in March 2025, conducted through the EU-M4all procedure in collaboration with the European Medicines Agency.
Who is eligible for lenacapavir PrEP in South Africa?
Lenacapavir is approved for adults and adolescents weighing at least 35 kg who are at risk of HIV-1 acquisition. Candidates must test HIV-negative before initiating treatment and before each subsequent injection.
What clinical evidence supports lenacapavir's efficacy for HIV PrEP?
The PURPOSE 1 trial (NCT04994509), a Phase 3 study of 5,268 adolescent girls and young women, demonstrated 100% efficacy for lenacapavir with zero infections observed in the treatment arm versus 16 infections in the oral PrEP comparator group.
Why is South Africa's approval significant for HIV prevention in Africa?
South Africa has approximately 7.8 million people living with HIV—the highest number globally. As the first African nation to approve lenacapavir, South Africa positions itself as a regulatory leader and may accelerate access across the continent where two-thirds of all people with HIV reside.
Primary Sources
- South African Health Products Regulatory Authority (SAHPRA). SAHPRA Registers Lenacapavir. October 27, 2025.
- U.S. Food and Drug Administration. Yeztugo (lenacapavir) Prescribing Information. June 2025.
- ClinicalTrials.gov. Pre-Exposure Prophylaxis Study of Lenacapavir and Emtricitabine/Tenofovir Alafenamide (NCT04994509). Accessed July 2025.
- European Medicines Agency. Yeytuo EPAR. July 2025.
- Gilead Sciences. Gilead Joins Partners for Delivery of First Shipments of Lenacapavir to Sub-Saharan Africa. November 18, 2025.
- UNAIDS. UNAIDS Executive Director encouraged by South Africa's continued leadership in responding to HIV. June 20, 2025.
Continue Exploring
Jump into the entities behind this story.
This article follows our editorial standards. Report a correction via editorial contact.
